Sarah E M Herman

Author PubWeight™ 11.98^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.	Blood	2010	4.69
2	Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.	Blood	2013	1.69
3	Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.	Blood	2014	1.58
4	Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals.	Cancer Cell	2012	1.52
5	ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.	Blood	2012	1.27
6	Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.	Blood	2012	0.90
7	Pharmacokinetics and tissue disposition of lenalidomide in mice.	AAPS J	2012	0.80